Literature DB >> 11245339

Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting.

S Dagar1, M Sekosan, I Rubinstein, H Onyüksel.   

Abstract

Vasoactive intestinal peptide (VIP) is a 28 amino acid neuropeptide with a wide range of biological activities. Receptors for VIP (VIP-R) are overexpressed in breast cancer, where they may have diagnostic and therapeutic implications. Although N-methyl nitrosourea (MNU)-induced breast cancer in rats is used extensively as a model to study mammary carcinogenesis, there is no information about the expression of VIP-R in this model. Therefore, the purpose of this study was to investigate the presence of VIP-R in MNU-induced breast cancer in rats so that this model can be used to perform studies involving VIP-R. Breast cancer was induced in 36-day-old virgin female Sprague-Dawley rats, by a single intravenous injection of MNU (50 mg/kg body weight). The breast tumors were detected 100-150 days after injection. The normal and cancerous rat breast tissue were excised and 20 micro sections were incubated with 40 nM fluorescein-labeled VIP (Fluo-VIP(TM)), in the presence and absence of 1000-fold excess unlabeled VIP, pituitary adenylate cyclase activating polypeptide (PACAP) or secretin. The sections were visualized under a fluorescence microscope and photographed. Fluo-VIP(TM) stained rat breast cancer tissue homogeneously and to a much greater extent than normal rat breast tissue (p < 0.05). This staining was specific as indicated by displacement of Fluo-VIP(TM) by excess unlabeled VIP and PACAP. Displacement of Fluo-VIP(TM) by secretin indicated the probable presence of VIP receptors of type VPAC1 (VIP receptor subtype 1) in the rat breast. These data suggest that, as in human breast cancer, VIP-R, predominantly of type VPAC1, are overexpressed in MNU-induced rat breast cancer tissue as compared to the normal rat breast tissue. Thus, MNU-induced rat breast cancer model can be used as a tool to study the functional role of VIP-R in human mammary carcinogenesis and VIP-R mediated active breast cancer targeting. This could have implications in the diagnosis, prognosis and therapy of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245339     DOI: 10.1023/a:1006406617497

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

Review 1.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

2.  Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.

Authors:  Ece Gülçür; Mentor Thaqi; Fatima Khaja; Antonina Kuzmis; Hayat Önyüksel
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

3.  VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.

Authors:  Aparna Dagar; Antonina Kuzmis; Israel Rubinstein; Marin Sekosan; Hayat Onyuksel
Journal:  Drug Deliv Transl Res       Date:  2012-12-01       Impact factor: 4.617

Review 4.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

5.  Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.

Authors:  Dulari Jayawardena; Grace Guzman; Ravinder K Gill; Waddah A Alrefai; Hayat Onyuksel; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-06       Impact factor: 4.052

6.  Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.

Authors:  Milena Veljkovic; Violeta Dopsaj; Milivoj Dopsaj; Donald R Branch; Nevena Veljkovic; Maria M Sakarellos-Daitsiotis; Veljko Veljkovic; Sanja Glisic; Alfonso Colombatti
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

7.  Protective effect of melatonin against Adriamycin-induced cardiotoxicity.

Authors:  Yan Zhang; Lixin Li; Cheng Xiang; Zhiqian Ma; Tian Ma; Shuchai Zhu
Journal:  Exp Ther Med       Date:  2013-03-06       Impact factor: 2.447

Review 8.  Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-29       Impact factor: 5.555

Review 9.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.